RayStation 11B

RayStation 11B is a comprehensive radiation therapy treatment planning system designed to enhance clinical decision-making and treatment accuracy through advanced dose calculation and imaging functionalities. It employs sophisticated algorithms for EQD2 dose computation, synthetic CT generation from CBCT, and detailed LET/RBE analysis for particle therapies, all validated for clinical utility.

RayStation 11B, developed by RaySearch Laboratories, is an advanced software system designed for comprehensive radiation therapy and medical oncology treatment planning, analysis, and administration. It operates through distinct modules: RayStation for core treatment planning, RayPhysics for the calibration of treatment machines and imaging systems, and RayTreat for managing plan delivery and treatment record integration. The system offers configurable functionality to assist clinicians by generating treatment plan proposals, which can then be reviewed, approved, and utilized for administering patient treatments, with a streamlined version named RayPlan 11B available. This iteration, RayStation 11B, introduces significant enhancements, including an EQD2 (two Gray equivalent dose) computation feature based on the linear quadratic biological model, enabling dose accumulation from photon and brachytherapy. It also incorporates two new algorithms for generating synthetic CT images from Cone-Beam CT (CBCT) data, thereby improving photon dose calculation accuracy by facilitating the use of HU values from these images. Furthermore, the system enhances support for particle therapy by enabling the computation and evaluation of dose-weighted Linear Energy Transfer (LET) for proton and light ion plans, providing deeper insights into radiobiological effects. Validation studies confirmed the clinical adequacy of these new features, affirming the system's performance and safety.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How do the two new algorithms for synthetic CT generation from CBCT differ in their methodology, and what are their respective impacts on dose calculation accuracy across various anatomical sites and imaging artifacts?; What is the specific mathematical implementation of the linear quadratic model for EQD2 dose computation, and how does the system handle variations in fractionation schemes or tissue-specific alpha/beta ratios?; For the handling of LET and RBE components, what models are used to calculate dose-weighted LET, and how does the system integrate LET information to influence RBE-weighted dose evaluation for proton and light ion plans beyond what was available in previous versions?; What were the specific validation metrics and tolerance levels used to deem the EQD2 dose computation, synthetic CT generation, and LET handling 'adequate for clinical use' during the respective validation processes (Clinical Evaluation for Brachy, CBCT Conversion validation, Proton PBS Monte Carlo validation)?; Considering the configurable nature of RayStation 11B, what are the default settings for the new features (EQD2, synthetic CT, LET), and what level of user expertise is assumed for customizing these parameters for optimal clinical outcomes?